[2]
Stewart, B.W.; Wild, C.P. World Cancer Report; 2014; IARC Publications: France, 2014.
[3]
Foo, J.; Michor, F. Evolution of acquired resistance to anti-cancer therapy. J. Theor. Biol., 2014, 355, 10.
[4]
Sadowski, M.C.; Pouwer, R.H.; Gunter, J.H.; Lubik, A.A.; Quinn, R.J.; Nelson, C.C. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. Oncotarget, 2014, 5(19), 9362.
[5]
Sippel, K.K.H.; Vyas, N.K.N.; Zhang, W.; Sankaran, B.; Quiocho, F.A.F.A. Crystal structure of the human fatty acid synthase enoyl- acyl carrier protein-reductase domain complexed with triclosan reveals allosteric protein-protein interface inhibition. J. Biol. Chem., 2014, 289(48), 33287.
[6]
Bharathkumar, I.; Gurubasavaraj, V.P.; Madhusudhan, N.P.; Viswanathan, B.I.; Sowmya, G.S.; Madhuri, K. Design, synthesis and evaluation of diphenyl ether analogues as antitubercular agents. RSC Advances, 2016, 6, 110571-110582.
[7]
De Schrijver, E.; Brusselmans, K.; Heyns, W.; Verhoeven, G.; Swinnen, J.V. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res., 2003, 63(13), 3799.
[8]
Deepa, P.R.; Vandhana, S.; Muthukumaran, S.; Umashankar, V.; Jayanthi, U.; Krishnakumar, S. Chemical inhibition of fatty acid synthase: Molecular docking analysis and biochemical validation in ocular cancer cells. J. Ocul. Biol. Dis. Infor., 2011, 3(4), 117.
[9]
Liu, X.; Shi, Y.; Giranda, V.L.; Luo, Y. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Mol. Cancer Ther., 2006, 5(3), 494.
[10]
Honkisz, E. Zieba-P.; Dorota, W.; Anna, K. The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells. Reprod. Toxicol., 2012, 34(3), 385-392.
[11]
Maier, T.; Leibundgut, M.; Ban, N. The crystal structure of a mammalian fatty acid synthase. Science (New York, N.Y.),, 2008, 321(5894), 1315.
[12]
Flavin, R.; Peluso, S.; Nguyen, P.; Loda, M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol., 2010, 6(4), 551.
[13]
Honkisz, E.; Zieba, P.D.; Wojtowicz, A.K. The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells. Reprod. Toxicol., 2012, 34(3), 385.
[14]
Gillmore, A.; Lauret, C.; Roberts, S.M. A route to the structure proposed for puetuberosanol and approaches to the natural products marshrin and phebalosin. Tetrahedron, 2003, 59, 4363-4375.
[15]
Talwar, S.; Jagani, H.V.; Nayak, P.G.; Kumar, N.; Kishore, A.; Bansal, P.; Shenoy, R.R.; Nandakumar, K. Toxicological evaluation of terminalia paniculata bark extract and its protective effect against CCl4-induced liver injury in rodents. BMC Complement. Altern. Med., 2013, 13(1), 127.
[16]
Reddy, N.D.; Shoja, M.H.; Jayashree, B.S.; Nayak, P.G.; Kumar, N.; Prasad, V.G.; Pai, K.S.R.; Rao, C.M. Chemico-Biological Interactions In vitro and in vivo evaluation of novel cinnamyl sulfonamide hydroxamate derivative against colon adenocarcinoma. Chemico-Biol. Int., 2015, 233, 81-94.
[17]
Gooch, J.L.; Yee, D. Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett., 1999, 144(1), 31-37.
[18]
Kuan, L.; Peng, C.L.; Run, L.; Xing, W. Dual AO/EB Staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med. Sci. Monit. Basic Res., 2015, 21, 15-20.
[26]
Cinu, T.A.; Sidhartha, S.K.; Indira, B.; Varadaraj, B.G.; Vishnu, P.S.; Shenoy, G.G. Design, synthesis and evaluation of antitubercular activity of Triclosan analogues. Arab. J. Chem., 2019, 12, 3316-3323.
[27]
Evans, D.A.; Katz, J.L.; West, T.R. Synthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine. Tetrahedron Lett., 1998, 39(19), 2937.
[28]
Sivaraman, S.; Sullivan, T.J.; Johnson, F.; Novichenok, P.; Cui, G.; Simmerling, C.; Tonge, P.J. Inhibition of the bacterial enoyl reductase fabi by triclosan: A structure-reactivity analysis of fabi inhibition by triclosan analogues. J. Med. Chem., 2004, 47, 509.
[29]
Menendez, J.A.; Colomer, R.; Lupu, R. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol. Rep., 2004, 12(2), 411-422.
[30]
Ruan, Z.; Hua, T.; Xue, Y.; Zhongguo, F. Clinical significance and expression of fatty acid synthase mRNA in lung cancer. Chinese J. lung. Cancer, 2006, 9(6), 502-505.
[31]
Axelsen, J.B.; Lotem, J.; Sachs, L.; Domany, E. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc. Natl. Acad. Sci. USA, 2007, 104(32), 13122-13127.
[32]
Kawasaki, M.; Kuwano, K.; Nakanishi, Y.; Hagimoto, N.; Takayama, K.; Pei, X.H.; Maeyama, T.; Yoshimi, M.; Hara, N. Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. Eur. J. Cancer, 2000, 36(5), 656-663.
[33]
Hellquist, H.B.; Olejnicka, B.; Jadner, M.; Andersson, T.; Sederholm, C. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report. Br. J. Cancer, 1997, 76(2), 175-179.